2026 NPPES data Oncology Pharmacist NPI 1932655693 PHARM.D
Verify on CMS →

Dazhi Liu, PHARM.D

Oncology Pharmacist in New York, New York.

This profile is drawn from the federal National Provider Identifier Registry (CMS NPPES), which lists more than 7 million U.S. healthcare providers - including 1,720 in Oncology Pharmacist, and covers specialty classification, practice address, and Medicare Part D prescribing data when reported. According to CMS, every field reflects the provider's official federal registration, see our methodology.

Federal data, no proprietary rating. We show these CMS records as-is - no composite score, no star rating, no editorial opinion layered on top.
Prescribing volume
79
Medicare Part D claims · 22 beneficiaries · Oncology Pharmacist avg: 160
Generic prescribing
54%
generic claims · 46% brand-name · higher generic rates reduce patient out-of-pocket costs
Compiled from official public sources by the PlainDoctor editorial team.

What the federal data shows

Dazhi Liu, PHARM.D filed 79 Medicare Part D claims in 2023 as a Oncology Pharmacist in New York, New York, prescribing 54% generic.

79
Part D claims, 2023
54%
generic prescribing

Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) - no proprietary rating or editorial opinion is applied.

Dazhi Liu, PHARM.D's Medicare Part D volume vs every U.S. prescriber

Total Medicare Part D claims, 2023, across all CMS prescribers nationally

79 0th percentile higher than 0% of 1,370,886 prescribers

0–200: 670,926 prescribers (49%). This entry sits in this band. 200–400: 182,923 prescribers (13%). Above this entry. 400–600: 90,619 prescribers (7%). Above this entry. 600–800: 56,224 prescribers (4%). Above this entry. 800–1,000: 40,919 prescribers (3%). Above this entry. 1,000–1,200: 31,827 prescribers (2%). Above this entry. 1,200–1,400: 26,224 prescribers (2%). Above this entry. 1,400–1,600: 21,710 prescribers (2%). Above this entry. 1,600–1,800: 19,072 prescribers (1%). Above this entry. 1,800–2,000: 16,451 prescribers (1%). Above this entry. 2K+: 213,991 prescribers (16%). Above this entry. This provider 0 2K+ every Part D prescriber (claims/yr), bucketed by value

Each bar is a band; taller bars hold more prescribers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Medicare Part D Prescriber Public Use File · 2023

What does the federal data show about Dazhi Liu, PHARM.D?

Quality data not reported

NPI registry status

Active

Issued 08/31/2016

NPI 1932655693

Primary specialty

Oncology Pharmacist

Niche

1,720 US NPIs in this specialty

Medicare Part D claims

79 51% vs specialty avg

2023 prescription claims

Specialty avg: 160

Specialty distribution in New York

How Oncology Pharmacist compares to other specialties among New York providers

New York providers
Student in an Organized Health Care Education/Training Program - 7.8%Student in an Organized Health Care Education/Training Program7.8%Registered Nurse - 5.2%Registered Nurse5.2%Clinical Social Worker - 4.9%Clinical Social Worker4.9%Social Worker - 4.5%Social Worker4.5%Speech-Language Pathologist - 4.5%Speech-Language Pathologist4.5%Licensed Practical Nurse - 4.3%Licensed Practical Nurse4.3%Oncology Pharmacist - 0%Oncology Pharmacist0%
Largest specialties in New York (% of in-state providers)

Board certification

Not published by CMS

CMS does not publish a per-provider board-certification field in NPPES. PlainDoctor does not have a reliable per-specialty certification rate to show for Oncology Pharmacist. Verify directly:

How MIPS and board certification work

The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.

Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).

Dazhi Liu, PHARM.D appears in the CMS NPPES registry as an Oncology Pharmacist provider holding PHARM.D credentials at 1275 YORK AVE, New York, NY, 10065, with a listed phone of (609) 480-6497. NPI 1932655693 was issued on 08/31/2016.

Medicare Part D records for calendar year 2023 show 79 prescription claims written by this provider, covering 22 Medicare beneficiaries and totaling roughly $17K in drug spend, split 46% brand-name and 54% generic by claim count.

Oncology Pharmacist is a narrow specialty nationwide, with 1,720 enrolled providers across 50 states and an average of 160 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline.

Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist, always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.

Practice Address

1275 YORK AVE
New York, NY 10065

Provider Details

NPI 1932655693
Specialty Oncology Pharmacist
Credentials PHARM.D
Gender Female
NPI Issued 08/31/2016

License & disciplinary context - New York NYSBPMC 2023 annual report

Aggregate state board data only, NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~100K New York medical licensees in 2023 - they are NOT specific to Dazhi Liu, PHARM.D. To verify Dazhi Liu, PHARM.D's current license status, search the NYSBPMC public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.

312
Total board actions, New York 2023
Across 302 cases
3.12
Actions per 1,000 licensees
New York statewide rate
probation
Most common action type
89 cases

NYSBPMC publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the New York disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.

Brand vs generic prescribing mix · Above average

Dazhi Liu, PHARM.D - brand share 46.0%
Oncology Pharmacist average

46% brand-name claims vs 54% generic, on 79 2023 Medicare Part D claims.

The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.

Medicare Part D Prescribing Data

CMS Medicare Part D prescriber-level data for calendar year 2023.

79
Total Claims
$17K
Total Drug Cost
22
Medicare Beneficiaries

Prescribing Breakdown

30-Day Fills
113
Total Day Supply
3,329
Brand vs Generic
46% brand / 54% generic
Brand Drug Cost
$16K
Generic Drug Cost
$398

Patient Demographics

Average Patient Age
71.0 years
Avg HCC Risk Score
2.84

Top Prescribed Drugs (Medicare Part D)

Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.

Drug Claims
Xarelto
Rivaroxaban
16

* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.

Oncology Pharmacist Overview

How Dazhi Liu, PHARM.D fits within the Oncology Pharmacist landscape nationally.

1,720
Oncology Pharmacist Providers in US
50
States with Oncology Pharmacist
160
Avg Claims per Provider

Dazhi Liu, PHARM.D's 79 claims are below the specialty average of 160.

Nearby Oncology Pharmacist Providers in New York

Other clinicians with the same primary specialty enrolled in New York, drawn from the same CMS NPPES roster as Liu.

Compare Oncology Pharmacist nationally: see state-by-state distribution →

Before you book an appointment

Use this federal record as your verification checklist, not as a recommendation.

  • Confirm the NPI record is current in the official CMS registry, providers update their own NPPES details, and moves can lag. Verify this NPI
  • Check the active license and any disciplinary history with the New York medical board, federal registration is not a license check. Credential verification guide
  • Weigh a second option: compare this provider with a nearby Oncology Pharmacist peer on Medicare volume and prescribing patterns. Compare providers

Medicare Part D and MIPS figures describe practice patterns in federal programs only, they are not quality ratings, and PlainDoctor does not rate, rank, or recommend providers.

Frequently Asked Questions

What is Dazhi Liu, PHARM.D's specialty?
Dazhi Liu, PHARM.D specializes in Oncology Pharmacist and practices in New York, New York. Credentials: PHARM.D.
How much does Dazhi Liu, PHARM.D prescribe under Medicare Part D?
In 2023, Dazhi Liu, PHARM.D wrote 79 Medicare Part D claims totaling $17K in drug costs for 22 beneficiaries.
Where is Dazhi Liu, PHARM.D located?
Dazhi Liu, PHARM.D is located at 1275 YORK AVE, New York, NY, 10065. Phone: (609) 480-6497.
What is Dazhi Liu, PHARM.D's NPI number?
Dazhi Liu, PHARM.D's National Provider Identifier (NPI) is 1932655693, issued on 08/31/2016.
Does Dazhi Liu, PHARM.D prescribe more brand-name or generic drugs?
Dazhi Liu, PHARM.D's prescribing is 46% brand-name and 54% generic drugs by claim count, with $16K in brand drug costs.
How many Oncology Pharmacist providers are there in the US?
There are 1,720 Oncology Pharmacist providers across 50 states in the US. The average Oncology Pharmacist provider writes 160 Medicare Part D claims per year.
What drugs does Dazhi Liu, PHARM.D prescribe most often?
Based on 2023 Medicare Part D data, Dazhi Liu, PHARM.D's most frequently prescribed drugs include Xarelto. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does Dazhi Liu, PHARM.D accept Medicare?
Dazhi Liu, PHARM.D appears in CMS Medicare data with 79 Part D claims and 22 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify Dazhi Liu, PHARM.D's credentials?
Dazhi Liu, PHARM.D's NPI is 1932655693 with credentials PHARM.D. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.

Data Sources

View source datasets and methodology notes
Provider Directory
CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
Specialty Classification
NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
Prescribing Data
CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
Limitations
Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.

See our complete data methodology for details on how we collect and process government data.

Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).

Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology

Compiled from official public sources by the PlainDoctor editorial team.

Every figure on PlainDoctor is rendered directly from the federal CMS NPPES registry, Medicare Part D, MIPS, and Open Payments records, no number is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.